SV1997000032A - Virosomas cationicos como sistema de transferencia para material genetico. - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico.

Info

Publication number
SV1997000032A
SV1997000032A SV1997000032A SV1997000032A SV1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A
Authority
SV
El Salvador
Prior art keywords
virosomes
transfer system
genetic material
cationic virosomes
membrane
Prior art date
Application number
SV1997000032A
Other languages
English (en)
Spanish (es)
Inventor
Klein Peter
Gluck Reinhard
Walti Ernst Rudolf
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of SV1997000032A publication Critical patent/SV1997000032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SV1997000032A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico. SV1997000032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
SV1997000032A true SV1997000032A (es) 1998-03-27

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000032A SV1997000032A (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico.

Country Status (28)

Country Link
US (1) US6210708B1 (enExample)
EP (1) EP0902682A2 (enExample)
JP (1) JP2000509404A (enExample)
KR (1) KR100536983B1 (enExample)
CN (1) CN1271992C (enExample)
AR (1) AR007054A1 (enExample)
AU (1) AU710170B2 (enExample)
BG (1) BG102880A (enExample)
BR (1) BR9709224A (enExample)
CA (1) CA2253561A1 (enExample)
CO (1) CO4600638A1 (enExample)
CZ (1) CZ299809B6 (enExample)
EA (1) EA003130B1 (enExample)
GT (1) GT199700058A (enExample)
HR (1) HRP970234B1 (enExample)
HU (1) HUP9901790A3 (enExample)
ID (1) ID17934A (enExample)
NO (1) NO327726B1 (enExample)
NZ (1) NZ332666A (enExample)
OA (1) OA10916A (enExample)
PA (1) PA8429201A1 (enExample)
PE (1) PE65198A1 (enExample)
PL (1) PL199201B1 (enExample)
SK (1) SK152698A3 (enExample)
SV (1) SV1997000032A (enExample)
TN (1) TNSN97080A1 (enExample)
WO (1) WO1997041834A1 (enExample)
ZA (1) ZA973885B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU9224398A (en) * 1997-09-08 1999-03-29 Promega Corporation Method of (in vivo) transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202809A2 (hu) * 1999-10-08 2002-12-28 Nika Health Products Limited Kationos DOSPER-viroszómák
DE50002682D1 (de) * 1999-12-17 2003-07-31 Schott Glas Induktiv aktivierbare zündkapsel für insassen-rückhaltesysteme und prüfschaltung für diese zündkapsel
WO2001052901A1 (en) * 2000-01-21 2001-07-26 Hisamitsu Pharmaceutical Co., Inc. Drugs for gene therapy
EP1409653A4 (en) * 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
AU2003288119B2 (en) * 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
EP2763696B1 (en) * 2011-10-07 2018-09-19 iSD Immunotech ApS Identification of the immunosuppressive domains in fusion proteins of enveloped rna viruses
US11241476B2 (en) 2016-09-27 2022-02-08 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
CA2086831C (en) * 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0762870B1 (en) * 1994-05-31 2002-09-11 INEX Pharmaceutical Corp. Virosome-mediated intracellular delivery of therapeutic agents
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
HRP970234A2 (en) 1998-06-30
GT199700058A (es) 1998-10-29
ZA973885B (en) 1998-11-06
AU710170B2 (en) 1999-09-16
EP0902682A2 (en) 1999-03-24
CO4600638A1 (es) 1998-05-08
NO327726B1 (no) 2009-09-14
EA003130B1 (ru) 2003-02-27
KR100536983B1 (ko) 2006-06-29
BG102880A (en) 1999-05-31
BR9709224A (pt) 1999-08-10
TNSN97080A1 (fr) 2005-03-15
ID17934A (id) 1998-02-12
CA2253561A1 (en) 1997-11-13
US6210708B1 (en) 2001-04-03
CN1225007A (zh) 1999-08-04
NZ332666A (en) 2000-05-26
PL199201B1 (pl) 2008-08-29
AU2776697A (en) 1997-11-26
KR20000010780A (ko) 2000-02-25
HRP970234B1 (en) 2002-04-30
NO985137L (no) 1999-01-04
HUP9901790A3 (en) 2010-11-29
JP2000509404A (ja) 2000-07-25
OA10916A (en) 2003-02-21
WO1997041834A1 (en) 1997-11-13
CZ361498A3 (cs) 1999-03-17
PA8429201A1 (es) 2000-05-24
NO985137D0 (no) 1998-11-04
AR007054A1 (es) 1999-10-13
SK152698A3 (en) 1999-05-07
CZ299809B6 (cs) 2008-12-03
EA199800992A1 (ru) 1999-06-24
HUP9901790A2 (hu) 1999-08-30
PE65198A1 (es) 1998-10-16
CN1271992C (zh) 2006-08-30
PL329853A1 (en) 1999-04-12

Similar Documents

Publication Publication Date Title
SV1997000032A (es) Virosomas cationicos como sistema de transferencia para material genetico.
ATE254664T1 (de) Renilla luciferase und green fluorescent protein fusionsgene
ES2119250T3 (es) Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.
FI964536A7 (fi) DNA-rakenne homologisen rekombinaation suorittamiseksi ja sen käyttöjä
ES2150894T1 (es) Vector de baculovirus modificado por proteinas de envoltura para terapia genica.
ES2146775T3 (es) Tratamiento de terapia genica de enfermedades del sistema nervioso central (snc) mediante un principio activo especifico de las celulas e independiente del ciclo celular.
DE69027526D1 (de) Herstellung von proteinen mittels homologer rekombination
ES2107537T3 (es) Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
PT1077072E (pt) Processo in vitro para produzir uma protese homologa de valvula cardiaca ou uma protese homologa de vaso sanguineo
MX9207397A (es) Recipientes para cultivo de celulas que tienen hileras interiores y metodo para cultivar celulas en los mismos.
EP0835099A4 (en) METHOD FOR CELL TRANSFECTION WITH LIPOSOMAL-ENCLOSED NUCLEIC ACIDS
ATE541940T1 (de) Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
ATE211166T1 (de) Zellkulturmatrix und biologisch abbaubare dreidimensionale matrix auf hyaluronsäurederivatbasis
BR9908499A (pt) Linhagens celulares embrionárias ousemelhantes a tronco produzidas portransplante nuclear de espécies cruzado
Cui et al. Knockdown of ASH1L methyltransferase induced apoptosis inhibiting proliferation and H3K36 methylation in bovine cumulus cells
Higashi et al. A novel transfection method for mammalian cells using calcium alginate microbeads
ES2165050T3 (es) Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos.
ATE400654T1 (de) Neues säugetiergen bc1-w, welches zur bc1-2 familie apoptose-kontrollierender gene gehört
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
DE3650065D1 (de) Invasive Mikroorganismen.
Li et al. Sulfonium lipids: synthesis and evaluation as DNA delivery vectors
De Lise et al. Electroporation-mediated DNA transfection of embryonic chick limb mesenchymal cells
Zhu et al. Efficient establishment of Guangxi Bama mini-pig transgenic fibroblasts via Xfect polymer transfection
UY26317A1 (es) Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
Funabashi et al. Sox2 regulatory region 2 sequence works as a DNA nuclear targeting sequence enhancing the efficiency of an exogenous gene expression in ES cells